These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33563895)

  • 1. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
    Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
    Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories.
    Lee J; Choi JH; Kim EH; Im J; Hwang H; Yang S; Lee JH; Lee K; Song J; Park S; Song SH
    Ann Lab Med; 2024 Nov; 44(6):518-528. PubMed ID: 39161319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
    Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
    Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bringing mass spectrometry into the care of patients with multiple myeloma.
    Murray DL
    Int J Hematol; 2022 Jun; 115(6):790-798. PubMed ID: 35471500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
    Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
    J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting monoclonal immunoglobulins in human serum using mass spectrometry.
    Mills JR; Barnidge DR; Murray DL
    Methods; 2015 Jun; 81():56-65. PubMed ID: 25916620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
    Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
    Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
    Mills JR; Kohlhagen MC; Dasari S; Vanderboom PM; Kyle RA; Katzmann JA; Willrich MA; Barnidge DR; Dispenzieri A; Murray DL
    Clin Chem; 2016 Oct; 62(10):1334-44. PubMed ID: 27540026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.
    Milani P; Murray DL; Barnidge DR; Kohlhagen MC; Mills JR; Merlini G; Dasari S; Dispenzieri A
    Am J Hematol; 2017 Aug; 92(8):772-779. PubMed ID: 28439985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
    Chapman JR; Thoren KL
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
    Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
    Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?
    Giles HV; Wechalekar A; Pratt G
    Br J Haematol; 2022 Aug; 198(4):641-653. PubMed ID: 35514140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down
    Deighan WI; Winton VJ; Melani RD; Anderson LC; McGee JP; Schachner LF; Barnidge D; Murray D; Alexander HD; Gibson DS; Deery MJ; McNicholl FP; McLaughlin J; Kelleher NL; Thomas PM
    Clin Chem Lab Med; 2021 Mar; 59(4):653-661. PubMed ID: 33079696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab.
    Kohlhagen M; Dasari S; Willrich M; Hetrick M; Netzel B; Dispenzieri A; Murray DL
    Clin Chem Lab Med; 2020 Aug; 59(1):155-163. PubMed ID: 32745067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
    Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
    Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.